CD19 CAR T Cells

Cell

Volumn 171, Issue 7, 2017, Pages 1471-

  Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; COMPLEMENTARY DNA; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN FUNCTION; ANTIGEN RECOGNITION; CELL STIMULATION; GENOME; HUMAN; IMMUNOCOMPETENT CELL; NEOPLASM; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOGRAFT; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANTIGENS, CD19; AUTOGRAFTS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOCYTE ACTIVATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85038012714     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.12.002     Document Type: Short Survey

References (10)

1. Brentjens, R.J., Latouche, J.B., Santos, E., Marti, F., Gong, M.C., Lyddane, C., King, P.D., Larson, S., Weiss, M., Rivière, I., Sadelain, M., Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9 (2003), 279–286.
2. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 2013, 177ra38.
3. Eshhar, Z., Waks, T., Gross, G., Schindler, D.G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90 (1993), 720–724.
4. Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32 (2009), 169–180.
5. Imai, C., Mihara, K., Andreansky, M., Nicholson, I.C., Pui, C.H., Geiger, T.L., Campana, D., Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18 (2004), 676–684.
6. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
7. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
8. Maher, J., Brentjens, R.J., Gunset, G., Rivière, I., Sadelain, M., Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20 (2002), 70–75.
9. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
10. Sadelain, M., and Mulligan, R.C. (1992). Efficient transduction of murine primary T lymphocytes. J. Gergely, eds. In 8th International Congress of Immunology.